Abstract:Abstract Background Impaired wound re-epithelialization contributes to cutaneous barrier reconstruction dysfunction. Recently, N6-methyladenosine (m6A) RNA modification has been shown to participate in the determination of RNA fate, and its aberration triggers the pathogenesis of numerous diseases. Howbeit, the function of m6A in wound re-epithelialization remains enigmatic. Methods Alkbh5‒/‒ mouse was constructed to study the rate of wound re-epithelialization after ALKBH5 ablation. Integrated high-throughput analysis combining methylated RNA immunoprecipitation sequencing (MeRIP-seq) and RNA-seq was used to identify the downstream target of ALKBH5. In vitro and in vivo rescue experiments were conducted to verify the role of the downstream target on the functional phenotype of ALKBH5-deficient cells or animals. Furthermore, the interacting reader protein and regulatory mechanisms were determined through RIP-qPCR, RNA pull–down, and RNA stability assays. Results ALKBH5 was specifically upregulated in the wound edge epidermis. Ablation of ALKBH5 suppressed keratinocyte migration and resulted in delayed wound re-epithelialization in Alkbh5‒/‒ mouse. Integrated high-throughput analysis revealed that PELI2, an E3 ubiquitin protein ligase, serves as the downstream target of ALKBH5. Concordantly, exogenous PELI2 supplementation partially rescued keratinocyte migration and accelerated re-epithelialization in ALKBH5-deficient cells, both in vitro and in vivo. In terms of its mechanism, ALKBH5 promoted PELI2 expression by removing the m6A modification from PELI2 mRNA and enhancing its stability in a YTHDF2-dependent manner. Conclusions This study identifies ALKBH5 as an endogenous accelerator of wound re-epithelialization, thereby benefiting the development of a reprogrammed m6A targeted therapy for refractory wounds. Graphical Abstract

Unraveling the landscape of m6A RNA methylation in wound healing and scars

Potential Genetic Therapies Based on M6a Methylation for Skin Regeneration: Wound Healing and Scars/keloids

The emerging roles of N6-methyladenosine RNA methylation in human cancers

M6a-Binding Proteins: the Emerging Crucial Performers in Epigenetics

The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

The m6A RNA Modification Modulates Gene Expression and Fibrosis-Related Pathways in Hypertrophic Scar

Epitranscriptomic m6A regulation following spinal cord injury

RNA N6-methyladenosine methylation and skin diseases

The role of m6A in angiogenesis and vascular diseases

Landscape of the epigenetic regulation in wound healing

Epitranscriptomic M6a Modification in the Stem Cell Field and Its Effects on Cell Death and Survival.

The Role of N6-Methyladenosine Modification in Microvascular Dysfunction

ALKBH5-mediated M6a Demethylation Fuels Cutaneous Wound Re-Epithelialization by Enhancing PELI2 Mrna Stability

m6A modification in non-coding RNAs: Mechanisms and potential therapeutic implications in fibrosis

Severe Burn Injury Significantly Alters the Gene Expression and M6a Methylation Tagging of Mrnas and Lncrnas in Human Skin

Multiple roles of m6A methylation in epithelial–mesenchymal transition

The role of m6A modification in the biological functions and diseases

N6-methyladenosine (m6A) RNA modification in fibrosis and collagen-related diseases

Genome-wide screening of m6A profiling of cutaneous wound healing in diabetic mice

The Critical Roles of M6a Modification in Metabolic Abnormality and Cardiovascular Diseases

Role of m6A RNA Methylation in Ischemic Stroke